Medical and Health Sciences | Article | Published 2024

CORRELATION ANALYSIS OF THE INCIDENCE OF POSTVIRAL SYNDROME WITH COMPARATIVE DATA OF ANTIVIRAL DRUGS

Authors:
Collection: INTERNATIONAL JOURNAL OF EUROPEAN RESEARCH OUTPUT
Keywords: Key words: correlation analysis, post-Covid syndrome, frequency of occurrence, antiviral drugs, comparative data.

Abstract

Abstract. In this article, we performed a correlation analysis between the incidence of postcovirus syndrome and the use of antiviral drugs in patients. Comparative data on the use of antiviral drugs in different groups of patients, with different clinical manifestations in patients hospitalized with this pathology were used. This analysis allowed us to detect a non-significant correlation between groups with the use of different antiviral drugs. Moreover, our results confirmed the importance of early use of antiviral therapy to prevent the development of postviral syndrome. The results obtained are an important step in increasing the efficiency of diagnosis and treatment of post-Covid syndrome, and also contribute to the more effective use of antiviral therapy in clinical practice.

References

  1. Literature:
  2. 1.
  3. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al.
  4. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis.
  5. 2020.
  6. 2.
  7. Chan KW, Wong VT, Tang SCW. COVID-19: An Update on the
  8. Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of
  9. 149
  10. Vol.3 No.2 FEBRUARY (2024)
  11. INTERNATIONAL JOURNAL OF EUROPEAN RESEARCH OUTPUT
  12. ISSN: 2053-3578
  13. I.F. 9.1
  14. Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus
  15. Disease. Am J Chin Med. 2020:1-26.
  16. 3.
  17. Yin-Xiao Du, Xiao-Ping Chen. Favipiravir: pharmacokinetics and concerns
  18. about clinical trials for 2019-nCoV infection // Clinical pharmacology and therapeutics. —
  19. 2020. — April 4.
  20. 4.
  21. Kimiyasu Shiraki, Tohru Daikoku. Favipiravir, an anti-influenza drug
  22. against life-threatening RNA virus infections // Pharmacology & Therapeutics. — 2020.
  23. — May (vol. 209). - P. 107512.
  24. 5.
  25. A team of authors led by L.N. Tuychiev. Temporary guidelines for the
  26. diagnosis and treatment of coronavirus infection. Tashkent 09/08/2020
  27. 6.
  28. Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, et al.
  29. Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral
  30. Group conference. Antiviral research. 2019; 167:45-67.
  31. 7.
  32. Gordon C. J., Tchesnokov E. P., Feng J. Y., Porter D. P., Götte M. The
  33. antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from
  34. Middle East respiratory syndrome coronavirus. // The Journal Of Biological Chemistry. —
  35. 2020. — April 10 (vol. 295, no. 15). — P. 4773—4779.
  36. 8.
  37. Agostini M. L., Andres E. L., Sims A. C., Graham R. L., Sheahan T. P., Lu
  38. X., Smith E. C., Case J. B., Feng J. Y., Jordan R., Ray A. S., Cihlar T., Siegel D., Mackman
  39. R. L., Clarke M. O. , Baric R. S., Denison M. R. Coronavirus Susceptibility to the Antiviral
  40. Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading
  41. Exoribonuclease. (English) // MBio. — 2018. — March 6 (vol. 9, no. 2).
  42. 9.
  43. Sheahan T. P., Sims A. C., Graham R. L., Menachery V. D., Gralinski L. E.,
  44. Case J. B., Leist S. R., Pyrc K., Feng J. Y., Trantcheva I., Bannister R., Park Y., Babusis
  45. D., Clarke M. O., Mackman R. L., Spahn J. E., Palmiotti C. A., Siegel D., Ray A. S., Cihlar
  46. T., Jordan R., Denison M. R., Baric R. S. Broad-spectrum antiviral GS-5734 inhibits both
  47. epidemic and zoonotic coronaviruses // Science Translational Medicine. — 2017. — June
  48. 28 (vol. 9, no. 396)
  49. 10.
  50. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of
  51. adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
  52. Lancet2020; 395:1054-62.
  53. 150
  54. Vol.3 No.2 FEBRUARY (2024)
  55. INTERNATIONAL JOURNAL OF EUROPEAN RESEARCH OUTPUT
  56. ISSN: 2053-3578
  57. 11.
  58. I.F. 9.1
  59. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in
  60. hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol2020; 5:802-10.
  61. 12.
  62. Puntmann VO, Karerge ML, Wieters I, et al. Cardiovascular magnetic
  63. resonance imaging findings in patients recently recovered from coronavirus disease 2019
  64. (COVID-19). JAMA Cardiol2020; 5:1265-73.
  65. 13.
  66. Carfi A, Bernabei R, Landi F, Gemelli COVID-19 Post-Acute Care Study
  67. Group. Gemelli v. C-P-ACSG. Persistent symptoms in patients after acute COVID-19.
  68. JAMA2020; 324:603-5.
  69. 14.
  70. Rajpal S, Tong MS, Borchers J . Cardiovascular magnetic resonance
  71. findings in athletes recovering from COVID-19 infection. JAMA Cardiol2021; 6:116-8.
  72. 15.
  73. Johansson M, Stolberg M, Runold M, et al. Long-term symptoms after
  74. COVID-19 manifesting as a variant of postural orthostatic tachycardia syndrome: the
  75. Swedish experience. JACC Case Rep2021; 3:573-80. DOI:10.1016/J.Jaccas.2021
  76. 16.
  77. Dani M., Dirksen A., Taraborrelli. et al. Autonomic dysfunction in “long
  78. COVID”: rationale, physiology and management strategies. Clean Med (London)2021;
  79. 21:E63-7.
Loading...
0

Views

0

Reads

0

Comments

0

Reviews

0

Liked

0

Shared

0

Bibliography

0

Citations

Like and share on

Cite this publication

Copy text below and use in your article